MSI2 and neoplasm: In colon adenomas driven by APC loss-of-function mutations, MSI2 acts as an inhibitor of known tumor suppressors, including LRIG1, BMPR1A, CDKN1A, and PTEN and sustained activation of mTORC1 (Wang et al., 2015).